Latest Amines Stories

First Product in Tris Pharma's Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris

2013-03-11 08:27:58

MONMOUTH JUNCTION, N.J., March 11, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, announced today receipt of a first milestone payment under its U.S. prescription cough/cold collaboration with Vernalis plc (Vernalis). This milestone recognizes the achievement by Tris of proof-of-concept (POC) for the first collaboration compound, CCP-01. Under the collaboration, POC required the successful...

Zoloft Lawsuits: Bernstein Liebhard LLP Notes Appointment of Special Master in Federal Zoloft Birth Defects Litigation

2013-03-10 23:02:25

The Firm is currently investigating Zoloft lawsuits on behalf of victims of alleged Zoloft birth defects. New York, New York (PRWEB) March 10, 2013 Zoloft lawsuits pending in a multidistrict litigation underway in U.S. District Court, Eastern District of Pennsylvania, are heading towards discovery, Bernstein Liebhard LLP reports. According to a Pretrial Order dated February 28th, the federal judge overseeing the Zoloft birth defects litigation has appointed a Special Discovery Master to...

Prozac Birth Defect Lawsuits Offered through Resource4thePeople

2013-03-06 23:02:29

Legal advice available for patients who used Prozac and other SSRI antidepressants that allegedly caused infants to suffer persistent pulmonary hypertension of the newborn, other birth defects San Diego, CA (PRWEB) March 06, 2013 http://www.resource4thepeople.com/defectivedrugs/prozac.html Resource4thePeople announced today that it is providing free consultations with attorneys for families who may have infants suffering from birth defects as a result of the use of Prozac or other SSRI...

Zoloft Lawsuit News: Bernstein Liebhard LLP Notes New Pretrial Order in Federal Zoloft Litigation Establishing Tentative Date for First Bellwether Trial

2013-03-03 23:01:35

The Firm is currently investigating Zoloft lawsuits on behalf of families whose child was born with a birth defect allegedly associated with their mother’s use of Zoloft during pregnancy. New York, New York (PRWEB) March 03, 2013 Zoloft lawsuits continue to move forward in the federal multidistrict litigation underway in U.S. District Court, Eastern District of Pennsylvania. According to a Pretrial Order issued on February 25th, the Zoloft litigation’s first trial is tentatively...

German Institute for Quality and Efficiency in Health Care (IQWiG) Publishes Dossier Evaluation within Early Benefit Assessment Process of PIXUVRI® (pixantrone)

2013-03-01 20:22:45

SEATTLE, March 1, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the private German Institute for Quality and Efficiency in Health Care (IQWiG) has published its report on the preliminary benefit assessment of PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). In May 2012, the European Commission (EC) granted conditional...

Lightwave Logic Delivers Perkinamine Indigo(TM) Coated Devices to Microelectronics Company

2013-02-28 16:32:00

Extensive Test Results of the Material's Electro-Optical Activity by the University of Colorado, Boulder (UCB) Exceeds Microelectronics Company's Requirements NEWARK, Del., Feb. 28, 2013 /PRNewswire/ -- Lightwave Logic, Inc. (OTCQB: LWLG), a technology company focused on the development of a Next Generation Non Linear Optical Polymer Materials Platform for applications in high speed fiber-optic data communications and optical computing, announced today that it has delivered prototype...

Darvon, Darvocet Lawyers at Wright & Schulte LLC Report on Decision Remanding Propoxyphene Lawsuit to California State Court

2013-02-27 23:03:25

Darvon, Darvocet Lawsuit Remanded to Los Angeles Superior Court, After U.S. District Judge Philip S. Gutierrez Determines Defendants Failed Show that Removal to Federal Court was Proper. Dayton, OH (PRWEB) February 27, 2013 Wright & Schulte LLC, an experienced drug injury law firm, reports that a federal judge has ruled that a lawsuit filed by alleged victims of Darvon and Darvocet side effects should be remanded back to Los Angeles Superior Court. In an Order dated February 20,...

Consumer Health Information Corporation Warns Poor Patient Adherence in Clinical Drug Trials May be Putting the Public at Risk

2013-02-12 08:31:02

MCLEAN, Va., Feb. 12, 2013 /PRNewswire/ -- Every person taking a prescription drug should be able to trust that the recommended dose is safe. This may not always be the case according to Dr. Dorothy L. Smith, President and CEO of Consumer Health Information Corporation. In the last ten years, many patients have developed unexpected toxicities from prescription drugs that have been on the market for 5-10 years. FDA has responded by cutting the doses of several drugs in half and...

Neuroplenish Offers A Bottle of Neuropathy Pain Relief Formula

2013-02-05 23:01:16

All-Natural Neuropathy pain relief formula, Neuroplenish launches free trial offer on its website. Salt Lake City, UT (PRWEB) February 05, 2013 Neuroplenish, maker of an all-natural remedy for neuropathy sufferers, is now offering a new promotion. Website visitors can order one bottle of Neuroplenish and pay only the postage of $9.95. The offer is limited to new customers and only one bottle per person may be ordered. Research shows that 20 million Americans and over half of all diabetes...

Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC)

2013-02-05 08:35:30

SAN FRANCISCO, Feb. 5, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today the start of a Phase 2 investigator-initiated study of etirinotecan pegol in patients with metastatic and recurrent NSCLC. The study is being conducted at the Abramson Cancer Center of the University of Pennsylvania under the direction of Charu Aggarwal, M.D., M.P.H., Assistant Professor of Oncology and Corey Langer, M.D., Professor of Oncology. "Patients with metastatic or recurrent...